Finanzen von Virax Biolabs Group Ltd (VRAX)VRAXVirax Biolabs Group Ltd

Evaluating the bottom line, Virax Biolabs Group Ltd maintains a gross margin of 80.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -160788.25%, while the net margin is -145725.93%. These profitability ratios, combined with a Return on Equity (ROE) of -80.87%, provide a clear picture of how effectively VRAX converts its operational activities into shareholder value.

In the context of the broader market, VRAX competes directly with industry leaders such as SHFS and PFSA. With a market capitalization of $2.34M, it holds a leading position in the sector. When comparing efficiency, VRAX's gross margin of 80.04% stands against SHFS's N/A and PFSA's N/A. Such benchmarking helps identify whether Virax Biolabs Group Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows a negative P/E ratio of -0.174 and a price-to-sales ratio of 188.61, which are concerning indicators of valuation and profitability.